We’re modeling the impact of NPLB’s proposal on insurance premiums and taxes, factoring in the higher (appropriate) utilization of drugs on savings from averted healthcare services, industry’s revenues and cost of goods sold (COGS), PBM rebates, and incentives for innovation.
Feel free to reach out with questions, concerns, or comments.
Contact us
